Thank you to everyone who visited our poster and took the time to speak with us at JAACT2025（https://aeplan.jp/jaact2025/）, held in Osaka from December 8–11.

The gene therapy symposium organized by Susumu Uchiyama (The University of Osaka / our CSO) was also a great success, featuring many engaging and insightful discussions.

At our poster, we highlighted a collaborative research outcome with The University of Osaka, including the following publication by Takahiro Maruno:

Maruno et al. Mol Ther Methods Clin Dev. 2025

“Variation of VP2 stoichiometry and deamidation of VP1 during production and their impacts on the transduction efficiency of AAV vectors”

https://www.cell.com/molecular-therapy-family/advances/fulltext/S2329-0501(25)00176-7

This study demonstrates, through correlation analysis of quality attributes across AAV manufacturing lots, that:

• VP stoichiometry
• Deamidation rates at N57 and N94 in VP1

are critical factors influencing AAV transduction efficiency.

✨Only through high-precision analytical technologies can truly critical quality attributes (CQAs) be identified.

We remain committed to advancing quality understanding and technological innovation for gene therapy vectors.